BNFC December 2022 Update

This update contains 2 significant changes, 3 dose changes, 2 new monographs and 2 new preparations.

Significant Changes:

• Herpesvirus infections: updated guidance for post-exposure prophylaxis
• Melatonin (Adaflex®, Ceyesto®): new indication for insomnia in patients with ADHD

Dose Changes:

• Budesonide [update to dosing for intranasal administration for rhinitis and nasal polyps]
• Lacosamide [update to age range for monotherapy and adjunctive treatment of focal seizures with or without secondary generalisation]
• Naloxone hydrochloride [update to neonatal dosing]

New Monographs:

• Imcivree® [setmelanotide]
• Oxbryta® [voxelotor]

New Preparations:

• Actimorph® [morphine]
• Dificlir® [fidaxomicin]

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes